<DOC>
	<DOCNO>NCT01032629</DOCNO>
	<brief_summary>The study ass canagliflozin ( JNJ-28431754 ) treatment patient type 2 diabetes mellitus ( T2DM ) regard cardiovascular ( CV ) risk major adverse cardiac event ( MACE ) . Other objective include evaluate overall safety , tolerability , effectiveness canagliflozin . The data study combine data CANVAS-R study ( Study Effects Canagliflozin Renal Endpoints Adult Subjects T2DM , NCT01989754 ) pre-specified integrated analysis CV safety outcome satisfy US FDA post-marketing requirement canagliflozin .</brief_summary>
	<brief_title>CANVAS - CANagliflozin cardioVascular Assessment Study</brief_title>
	<detailed_description>The study evaluate canagliflozin compare placebo CV event include CV death , heart attack , stroke patient T2DM , whose diabetes well control begin study history CV event high risk CV event . The study include 3 substudies compare effectiveness lower blood glucose assess safety canagliflozin relative placebo patient receive specific commonly-used diabetes agent . 4,330 participant randomly assign treatment 1 2 dos canagliflozin ( 100 300 mg ) placebo , 1:1:1 ratio . This study originally design last 9 year . As per FDA post-marketing requirement canagliflozin , study 's last subject last visit occur enough MACE event ( ie , CV death , nonfatal myocardial infarction , nonfatal stroke ) accumulate CANVAS ( study ) CANVAS-R study , project occur prior April 2017 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Patients must diagnosis type 2 diabetes mellitus great equal ( &gt; = ) 30 yrs old history cardiovascular ( CV ) event , &gt; = 50 yr old high risk CV event Patients must inadequate diabetes control ( define glycosylated hemoglobin great equal 7.0 % less equal 10.5 % screening ) either ( 1 ) currently diabetes drug therapy ( 2 ) therapy approve class diabetes drug A history diabetic ketoacidosis , type 1 diabetes mellitus , pancreas betacell transplantation , diabetes secondary pancreatitis pancreatectomy History one severe hypoglycemic ( ie , low blood sugar ) episode within 6 month screen</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Cardiovascular risk</keyword>
	<keyword>Cardiovascular outcome</keyword>
	<keyword>Canagliflozin ( JNJ-28431754 )</keyword>
	<keyword>Placebo</keyword>
</DOC>